RxDoctor Payments Data

Curtis Child, APRN

Nurse Practitioner · Las Vegas, NVNPI 1144327099

Payments from drug & device makers

$4,288in general payments, 2019–2025

Across 205 payments — averaging $20.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$549
  • Vanda Pharmaceuticals Inc.$486
  • AbbVie$419
  • Johnson & Johnson$375
  • Neurocrine Biosciences, Inc.$279
  • plus $916 from 9 others

What the payments were for

  • Food & beverage$4,24199%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,288 in reported general payments places this provider in the 90th percentile of 933 nurse practitioner providers in Nevada.

See all nurse practitioner providers in Nevada

Medicare billing

Part B allowed, 2024
$4,169
Medicare patients
18
Services billed
53

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole129$357,670
Invega SustennaPaliperidone Palmitate113$356,536
AustedoDeutetrabenazine35$346,167
AristadaAripiprazole Lauroxil78$225,298
VraylarCariprazine Hcl79$48,698
PerserisRisperidone15$43,030
RexultiBrexpiprazole26$34,579
LybalviOlanzapine/Samidorphan Malate20$32,209
Lurasidone Hcl159$19,278
QelbreeViloxazine Hcl80$17,408
SaphrisAsenapine Maleate14$17,020
TopamaxTopiramate26$12,786
SpravatoEsketamine Hcl15$11,618
TrintellixVortioxetine Hydrobromide64$11,566
VyvanseLisdexamfetamine Dimesylate27$10,357

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$1,265$392,248155 claims
Johnson & JohnsonInvega Sustenna, Spravato$375$368,154128 claims
Teva Pharmaceuticals USA, Inc.Austedo$136$346,16735 claims
Alkermes, Inc.Aristada, Lybalvi$179$257,50798 claims
AbbVieVraylar, Saphris$419$65,71893 claims
Indivior Inc.Perseris$98$43,03015 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$549$9,53322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 933 nurse practitioner providers in Nevada.

Other nurse practitioner in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →